EcoDrugPlus

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSKMAG00000012423
Gene Symbol: LOC108244163
2 Cross references
69 Possible Orthologues:

Voltage-Dependent N-Type Calcium Channel Subunit Alpha-1b-Like

Ensembl ID : ENSKMAG00000002746
Gene Symbol: LOC108245630
3 Cross references
219 Possible Orthologues:

Voltage-Dependent T-Type Calcium Channel Subunit Alpha-1i-Like

Ensembl ID : ENSKMAG00000011492
Gene Symbol: LOC108231691
2 Cross references
183 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSKMAG00000007102
Gene Symbol: LOC108250902
2 Cross references
190 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSKMAG00000018899
Gene Symbol: LOC108242680
3 Cross references
167 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSKMAG00000020688
Gene Symbol: LOC108239183
3 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSKMAG00000018912
Gene Symbol: LOC108242692
3 Cross references
182 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSKMAG00000018871
Gene Symbol: LOC108242627
4 Cross references
184 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-1-Like

Ensembl ID : ENSKMAG00000016599
Gene Symbol: LOC108235077
3 Cross references
226 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSKMAG00000016364
Gene Symbol: XDH
3 Cross references
208 Possible Orthologues:

Ensembl ID : ENSKMAG00000014911
Gene Symbol: -
Cross references: -
144 Possible Orthologues:

Ensembl ID : ENSKMAG00000002900
Gene Symbol: -
Cross references: -
235 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).